Great article, thank you. I did cardiac rehab after an MI and it was the best! Having my heart monitored during exercise with nurses and therapists watching greatly reduced my anxiety about starting exercise again. Also, walking the treadmill gave the nutritionist the opportunity to talk to me while I was a captive audience.
Does your book discuss the use of PCSK9 inhibitors compared to statins? From what I have read, the main impediment to PCSK9 inhibitors is cost and, in the future, they may supplant statins with fewer side effects. If so, I am curious whether seeking PCSK9 inhibitors now rather than later makes sense if cost is not a primary concern.
Hi Dr. Barrett-thanks so much for your quick reply.
I agree with your point about being married to a central thesis. I’m not in any particular camp myself.
I’m just an anesthesiologist, thankfully not a cardiologist or, heaven forbid, a lipidologist and struggle to understand the nuances of lipid management.
Thank you for the AHA journal link(another paper to read!).
And thank you for all the information you provide.
In a strange coincidence, just when I received your latest Substack issue, I also received the latest Substack from Nina Teicholz and Gary Taubes. They discuss a recent British Medical Journal article from March of 2024, citing the lowest risk for long term mortality is in the population with LDL-C levels between 100-189 mg/dl.
I often cut and paste your details in when I have patients who could do with reading your articles! Thank you
Great article, thank you. I did cardiac rehab after an MI and it was the best! Having my heart monitored during exercise with nurses and therapists watching greatly reduced my anxiety about starting exercise again. Also, walking the treadmill gave the nutritionist the opportunity to talk to me while I was a captive audience.
Does your book discuss the use of PCSK9 inhibitors compared to statins? From what I have read, the main impediment to PCSK9 inhibitors is cost and, in the future, they may supplant statins with fewer side effects. If so, I am curious whether seeking PCSK9 inhibitors now rather than later makes sense if cost is not a primary concern.
Encouraging message that there is still time to close the gate...that the horse is only thinking of bolting. Thanks Paddy
Hi Dr. Barrett-thanks so much for your quick reply.
I agree with your point about being married to a central thesis. I’m not in any particular camp myself.
I’m just an anesthesiologist, thankfully not a cardiologist or, heaven forbid, a lipidologist and struggle to understand the nuances of lipid management.
Thank you for the AHA journal link(another paper to read!).
And thank you for all the information you provide.
Bill
Hello Dr. Barrett;
In a strange coincidence, just when I received your latest Substack issue, I also received the latest Substack from Nina Teicholz and Gary Taubes. They discuss a recent British Medical Journal article from March of 2024, citing the lowest risk for long term mortality is in the population with LDL-C levels between 100-189 mg/dl.
https://bmjopen.bmj.com/content/14/3/e077949.
I’m interested to hear your thoughts.
Thanks for all your work.
Bill